Urinalysis Testing Products Market Size
The global urinalysis testing products market is projected to grow at a CAGR of 7.3% during 2026–2035. Growing geriatric population and age-related disorders are increasing demand for urinalysis products, particularly for detecting urinary tract infections, kidney disorders and other conditions that become more prevalent with age.
The simplicity, affordability and accessibility of urinalysis testing make it an important routine screening tool across hospitals, diagnostic centers, laboratories and homecare settings, supporting wider adoption of testing products.
Increasing adoption of automated urinalysis technologies such as automated urine analyzers, digital microscopy and integrated testing systems is improving testing throughput, standardization and analytical efficiency while reducing the labor associated with manual urine-sediment analysis.
Urinalysis Testing Products Market Key Takeaways
The market expands at a 7.3% CAGR during 2026–2035, taking the 2025 market index from 100 to approximately 202.3 by 2035.
The U.S. clinical demand pool remains substantial. CDC estimates 37 million adults have CKD, and approximately 87% remain unaware that they have the condition, reinforcing the need for routine testing capable of identifying protein or albumin abnormalities before advanced disease develops.
Among U.S. adults with diabetes, approximately 38% have CKD, strengthening the role of routine urine testing within metabolic disease monitoring.
Urinalysis volume is also high in acute-care settings. Beckman Coulter reports that approximately one in three U.S. emergency-department encounters includes urine testing, while urine analysis is performed in a large proportion of admitted patients.
Current urine chemistry throughput ranges from 240 samples per hour on Siemens CLINITEK Novus and Roche cobas u 601 to 300 samples per hour on Beckman Coulter's DxU 1800c.
Siemens' compact Atellica UAS 60 provides digital sediment imaging at up to 60 samples per hour in a footprint of approximately 0.1 m², showing how automated microscopy is moving beyond large central laboratories into smaller facilities.
Urinalysis Testing Products Market Description
The urinalysis testing products market is moving beyond the traditional model of dipstick screening followed by manual microscopic review.
Routine urine testing remains one of the most frequently used diagnostic procedures because a single specimen can provide information relevant to urinary tract infection, kidney disease, diabetes, liver abnormalities, hematuria, proteinuria and broader metabolic assessment.
The commercial market, however, is changing because laboratories are no longer satisfied with simply replacing manual strip interpretation with automated readers.
The next investment cycle is centered on integrating urine chemistry, sediment analysis, digital imaging, reflex rules and laboratory information systems into one standardized workflow.
A urine sample can now move through automated chemistry analysis and, depending on predefined results, be routed automatically into particle analysis or digital sediment imaging. Samples meeting laboratory-defined release rules can be reported without repeated manual intervention, while abnormal samples are escalated for review.
This changes the value proposition of urinalysis equipment.
The strongest systems are increasingly evaluated according to:
how many samples can be released without manual intervention;
how reliably chemistry and sediment results are connected;
how much microscopy workload can be eliminated;
whether albumin and creatinine markers can be incorporated into routine kidney screening;
and
how efficiently abnormal results are routed for additional testing.
Beckman Coulter's 2026 DxU 1800 launch illustrates this transition. The fully automated system combines urine chemistry with microscopy and is designed to reduce fragmented workflows between the two analytical stages. The company states that its underlying microscopy architecture can reduce manual microscopic review to below 3% in suitable workflows.
Urinalysis is therefore becoming less of a stand-alone laboratory bench test and more of a reflex diagnostic control layer connecting routine screening with kidney assessment, UTI evaluation and additional confirmatory testing.
Executive Summary
The urinalysis testing products market is entering a new automation cycle.
The existing DataM market structure identifies instruments as the dominant product category, supported by continued migration from visual strip reading and manual microscopy toward automated urine chemistry and sediment systems.
The clinical demand base remains broad.
CDC's updated kidney disease assessment reports that approximately 37 million U.S. adults, or 14%, have chronic kidney disease, while about 87% of adults with CKD are unaware of their condition. CKD prevalence reaches 38% among adults with diabetes and 21% among adults with high blood pressure.
These numbers create an important testing opportunity because urine protein and albumin measurements can identify kidney damage before advanced clinical symptoms appear.
CDC specifically identifies urine protein testing as an important part of CKD detection.
At the same time, hospital and reference laboratories face increasing pressure to process large sample volumes with fewer manual steps.
Current high-throughput systems illustrate how far automation has progressed.
Siemens Healthineers' CLINITEK Novus processes up to 240 samples per hour and can load 200 samples simultaneously.
Roche's cobas u 601 similarly provides throughput of 240 urine chemistry samples per hour, while the cobas u 701 sediment analyzer processes up to 116 samples per hour.
Beckman Coulter's new DxU 1800c chemistry platform reaches 300 samples per hour, increasing the throughput benchmark for high-volume urinalysis.
The strongest technology shift, however, is not simply faster strips.
It is the migration toward automated reflexing, digital microscopy and auto-verification.
Sysmex's UN-9000 architecture includes rules-based reflexing across compatible analyzers, while its wider UN-Series combines urine chemistry, particle analysis and digital imaging within modular workflows.
The future market will therefore be defined by how effectively each platform converts a urine specimen into an actionable, standardized result with the least manual intervention.
Reflex Automation Is Becoming the New Competitive Architecture
Traditional urinalysis workflows often required several independent steps.
A technician analysed the urine chemistry strip.
An abnormal result triggered sediment preparation.
The sediment was centrifuged.
A slide was prepared.
Particles were manually reviewed under a microscope.
Results from chemistry and microscopy then had to be combined before release.
Every handoff added time and operator variability.
Integrated platforms increasingly automate these decisions.
Sysmex's UN-Series combines urine chemistry, particle counting and digital imaging, while its UN-9000 supports rules-based reflexing between compatible analyzers.
This means laboratories can define different workflows for different sample types.
A normal urine specimen may proceed directly to release.
A sample with leukocytes, nitrite or abnormal particles can automatically trigger further analysis.
A suspected pathological cast or atypical cell pattern can be routed for digital review.
The market is therefore moving from automation of individual tests toward automation of diagnostic decisions between tests.
That distinction is commercially important.
The system that processes the highest number of strips per hour may not create the highest laboratory value if it still generates large manual review workloads.
Future procurement should increasingly evaluate:
reflex efficiency;
auto-release percentage;
manual review percentage;
flagging accuracy;
and turnaround time per reportable specimen.
Digital Microscopy Is Challenging Routine Manual Sediment Review
Urine sediment analysis has historically depended heavily on trained microscopy personnel.
That creates several problems.
Particle classification can vary between observers.
Microscopy is labor intensive.
Training is difficult.
High-volume laboratories can accumulate large review backlogs.
Digital sediment systems address these limitations by capturing images and automatically categorizing common particles.
Siemens' Atellica UAS 60 uses high-resolution full-field imaging and automated particle classification. The compact system processes up to 60 samples per hour and stores up to 10,000 patient results with associated images.
The Atellica 1500 integrates digital sediment microscopy with automated chemistry and supports up to 240 samples per hour at system level.
Beckman Coulter's iQ200 architecture automatically classifies 12 major particle types and 27 subcategories, reducing the amount of manual categorization required.
Sysmex uses a different analytical approach by combining fluorescent flow cytometry for particle differentiation with digital imaging where further visual confirmation is required.
The future competitive market will therefore include several sediment-analysis architectures rather than one single winning technology.
Chemistry and Sediment Are Becoming One Purchasing Decision
The existing DataM page identifies automated instruments as the key product driver, but the more important commercial transition is integration between chemistry and sediment systems.
Historically, laboratories could purchase strip readers and microscopy solutions independently.
That approach can create fragmented workflows.
Modern systems increasingly connect both analytical stages.
Siemens' Atellica 1500 combines CLINITEK Novus urine chemistry with the Atellica UAS 800 sediment analyzer in an integrated platform.
Beckman Coulter's 2026 DxU 1800 system similarly combines the DxU 1800c chemistry analyzer with DxU Iris microscopy.
Sysmex's modular UN-Series integrates urine chemistry, fluorescent particle analysis and optional digital imaging.
Roche follows a modular architecture through cobas u 601 urine chemistry and cobas u 701 sediment analysis.
This creates stronger instrument-platform competition.
Once chemistry and microscopy are validated around one workflow, switching vendors can require:
new validation;
new consumables;
retraining;
LIS reconfiguration;
and changes to laboratory decision rules.
Installed-base economics therefore become increasingly important.
Kidney-Risk Screening Is Expanding the Value of Routine Urinalysis
One of the strongest future market opportunities lies in connecting routine urinalysis with early kidney disease detection.
CKD can progress for years without obvious symptoms.
CDC estimates that 87% of adults with CKD are unaware they have the disease.
Urine testing provides an important route to earlier identification because abnormal protein or albumin excretion can indicate kidney damage.
The commercial opportunity is moving beyond conventional semi-quantitative strip protein.
Modern urinalysis platforms increasingly incorporate or plan to incorporate:
urine albumin;
urine creatinine;
albumin-to-creatinine ratio;
and protein-to-creatinine ratio.
Siemens' Atellica 1500 menu includes albumin, creatinine, albumin-to-creatinine ratio and protein-to-creatinine ratio within compatible cassette configurations.
Beckman Coulter's new DxU architecture is also being developed with expanded chemistry capability including creatinine and microalbumin.
This is strategically important because urine chemistry can begin to move from a broad screening test toward a more direct kidney-risk assessment pathway.
Diabetes Is Turning Urine Testing into a Chronic Monitoring Opportunity
Diabetes remains strongly connected with kidney disease.
CDC's 2026 data estimate that 38% of adults with diabetes have chronic kidney disease, while the burden is even higher among some specific diabetes populations.
This creates an important overlap between diabetes management and urinalysis products.
Routine diabetes management may require assessment of:
urine albumin;
protein;
glucose;
ketones;
and other indicators depending on clinical context.
The long-term commercial opportunity therefore extends beyond acute urinalysis.
Testing products can become embedded within recurring chronic disease pathways.
A urine analyzer capable of integrating routine chemistry with albumin-creatinine assessment can potentially capture greater testing value from the same specimen.
UTI Testing Is Moving toward Smarter Reflex-to-Culture Workflows
Urinalysis is frequently used when a urinary tract infection is suspected.
Leukocyte esterase, nitrite, white blood cells and bacteria can support clinical evaluation, but conventional urinalysis does not by itself provide the full organism identification and antimicrobial susceptibility information available from urine culture.
The operational challenge is deciding which samples actually require microbiology workup.
Sending every urine sample for culture creates unnecessary laboratory cost.
Missing cultures in clinically important samples creates another risk.
Automated particle systems can therefore become culture-screening tools.
Beckman Coulter's iQ200 workflow includes a urine-culture indicator designed to identify specimens that may require microbiological follow-up.
Sysmex's fluorescent flow-cytometry architecture can automatically identify and quantify urine particles, including bacteria and white blood cells, before samples move to additional testing.
The commercial opportunity is increasingly around reflex-to-culture efficiency, not simply UTI strip volume.
Auto-Verification Is Reducing Manual Result Release
Clinical laboratories are facing sustained pressure to manage higher testing volumes without equivalent increases in specialist staffing.
This makes auto-verification commercially important.
Automated urinalysis platforms can apply predefined laboratory criteria and release results that fall within acceptable rules.
Only exceptions require human review.
Beckman Coulter's iQ200 includes Edit-Free Release technology designed to automatically release appropriate results according to user-defined criteria.
Sysmex's UN-Series extends this concept into configurable reflex workflows across urine chemistry, particle analysis and digital imaging.
The market is therefore beginning to compete around manual-touch reduction.
This can become a stronger economic metric than instrument price because labor cost continues throughout the life of the analyzer.
Consumables Are the Recurring Revenue Engine
Although the existing DataM source identifies instruments as the dominant product category, consumables create the recurring revenue layer associated with the installed instrument base.
The segment includes:
urinalysis strips;
test cassettes;
reagents;
quality-control materials;
cuvettes;
collection containers;
and other disposable components.
Siemens CLINITEK Novus uses cassettes containing at least 450 test sets, while Atellica sediment systems rely on dedicated cuvette cartridges.
Roche's cobas u 601 uses cassettes containing 400 test strips.
Consumables therefore create strong platform economics.
Once a laboratory commits to an analyzer, a corresponding recurring consumable stream can continue for several years.
This makes installed-base growth particularly valuable for manufacturers.
Point-of-Care Urinalysis Remains Strategically Important
Not every urine sample needs to enter a high-volume central laboratory.
Primary care, urgent care, outpatient clinics and smaller diagnostic facilities often require immediate semi-quantitative results.
Point-of-care strip readers offer a different commercial value proposition.
Their strength is:
small footprint;
fast result availability;
low infrastructure requirement;
and ease of use.
Siemens maintains a broad CLINITEK point-of-care portfolio alongside high-throughput laboratory systems.
The market is therefore separating into two parallel automation tracks.
Large laboratories are moving toward fully integrated chemistry and microscopy.
Smaller sites are moving toward standardized compact digital readers rather than manual visual interpretation.
Compact Digital Microscopy Opens a Mid-Volume Market
Historically, sophisticated digital sediment systems were primarily justified in large laboratories.
Compact platforms are changing that.
The Atellica UAS 60 requires approximately 0.1 square metres of footprint, operates at up to 60 tests per hour, and uses only cuvettes rather than liquid sediment reagents.
This creates a new category between manual microscopy and large high-throughput automation.
Potential customers include:
community laboratories;
regional hospitals;
specialty clinics;
and backup laboratories within large health systems.
This segment can expand automated sediment analysis without requiring the throughput economics of a central reference laboratory.
Informatics Is Becoming Part of the Urinalysis Product
Urinalysis generates several classes of data:
chemical results;
particle counts;
microscopic images;
flags;
quality-control information;
and reflex decisions.
Managing these results manually reduces some of the benefits created by instrument automation.
Digital integration is therefore becoming more important.
Sysmex's UN-Series includes Urinalysis Data Manager software and supports rules-based workflows. Its BeyondCare Quality Monitor can proactively monitor analyzer performance and identify potential errors.
Siemens CLINITEK Novus supports LIS connectivity using standard laboratory interfaces, while patient and quality-control results are stored onboard.
The long-term market opportunity increasingly includes:
remote monitoring;
auto-verification;
instrument fleet management;
and cross-site standardization.
Market Dynamics
Market Drivers
The strongest driver is the large volume of routine urine testing across healthcare systems.
Urinalysis is inexpensive relative to many molecular and imaging diagnostics, broadly available and capable of providing information across several disease pathways.
CKD provides a particularly important growth driver because a substantial proportion of affected adults remain undiagnosed.
Approximately 37 million U.S. adults have CKD, while 87% are unaware of the condition.
Diabetes creates another recurring testing pool because CKD is common among people with diabetes.
Laboratory staffing constraints support automation investment.
High-throughput laboratories increasingly need to reduce manual microscopy and result verification.
Point-of-care expansion provides another growth channel.
Finally, current instrument launches are widening the available automation spectrum from compact analyzers processing 60 samples per hour to high-throughput systems handling 300 samples per hour.
Market Restraints
The major restraint is that conventional urine dipsticks remain inexpensive and widely available.
This can slow adoption of premium automation in facilities where testing volume is insufficient to justify capital expenditure.
Urine testing also remains sensitive to specimen quality.
Collection contamination, storage delay and handling errors can influence results even when analytical equipment performs correctly.
Automation does not eliminate the need for expert review.
Certain casts, crystals, atypical cells and unusual sediment findings may still require trained interpretation.
A comparative evaluation of digital sediment analyzers found that some particle categories benefited materially from operator review, illustrating why complete elimination of laboratory expertise is not appropriate.
Instrument fragmentation creates another restraint.
Laboratories with chemistry, microscopy and LIS products from multiple vendors can face integration and maintenance complexity.
Finally, capital cost and proprietary consumables can make long-term total cost of ownership an important purchasing barrier.
Market Opportunities
The strongest opportunity is fully integrated chemistry + sediment automation.
The 2026 U.S. launch of Beckman Coulter's DxU 1800 demonstrates continuing supplier investment in this segment.
Kidney-risk screening represents another significant opportunity as urine albumin and creatinine measurements become integrated into routine laboratory workflows.
Compact digital microscopy opens automation to smaller laboratories that previously depended on manual sediment review.
Rules-based reflex testing can reduce unnecessary microscopy and culture workload.
Digital auto-verification can reduce routine result-release labor.
Consumables provide recurring growth alongside analyzer placements.
Point-of-care connectivity remains attractive because it can standardize strip interpretation outside central laboratories.
Finally, informatics and remote quality management provide additional recurring service revenue around installed instrument fleets.
Segmentation Analysis
By Product Type
Instruments
Instruments represent the leading product segment within the DataM market structure.
The category is becoming increasingly diverse.
High-volume automated urine chemistry systems now process between 240 and 300 samples per hour depending on platform.
Compact sediment systems such as Atellica UAS 60 operate at up to 60 samples per hour, while integrated platforms combine strip chemistry with automated sediment analysis.
Instrument competition is increasingly segmented into:
high-throughput central laboratory systems;
integrated chemistry-and-sediment platforms;
compact sediment analyzers;
semi-automated chemistry readers;
and point-of-care strip readers.
The strongest growth should come from systems capable of reducing manual review rather than simply reproducing visual strip reading electronically.
Consumables
Consumables provide the recurring revenue associated with instrument placements.
The category includes reagent strips, cassettes, cuvettes, quality controls and disposable sampling products.
The economics can be substantial.
CLINITEK Novus cassettes support at least 450 test sets, while Roche's cobas u pack contains 400 strips per cassette.
As analyzer installations expand, consumables can generate more predictable recurring revenue than capital equipment alone.
By Application
Urinary Tract Infections
UTI evaluation remains one of the most important applications.
Chemistry results such as leukocyte esterase and nitrite can be combined with particle analysis for white blood cells and bacteria.
The next technology step is automated determination of which samples require culture.
This gives integrated urinalysis platforms a larger role in antimicrobial stewardship and laboratory workload management.
Kidney Diseases
Kidney disease represents one of the strongest strategic growth segments.
CDC estimates 37 million U.S. adults have CKD, with only a small minority aware of their condition.
Urine testing can detect protein or albumin abnormalities associated with kidney damage.
The opportunity increasingly shifts from generic protein detection toward more quantitative albumin-creatinine assessment.
Diabetes
Diabetes supports repeat urinalysis through both metabolic monitoring and kidney-risk assessment.
Approximately 38% of U.S. adults with diabetes have CKD, strengthening the connection between diabetes care and urine-based kidney testing.
Platforms that combine glucose, ketones, protein, albumin and creatinine measurements can capture greater diagnostic value from diabetic monitoring pathways.
Liver Diseases
Bilirubin and urobilinogen remain routine urine chemistry parameters that can indicate abnormalities requiring further clinical assessment.
This application should remain primarily embedded within broad routine urinalysis rather than developing into a dedicated liver-testing market.
Other Applications
Other applications include hematuria investigation, pregnancy-related testing, metabolic abnormalities and broader routine health screening.
The commercial advantage of urinalysis is its ability to provide several diagnostic signals from one low-complexity specimen.
By End User
Hospitals
Hospitals remain one of the most important end-user groups because urinalysis is commonly ordered across emergency care, inpatient medicine, nephrology, urology and metabolic disease management.
Beckman Coulter reports that approximately one in three U.S. emergency department encounters includes urine testing.
High-volume hospitals increasingly require integrated platforms capable of combining chemistry, microscopy and automated result release.
Diagnostic Centers and Reference Laboratories
Reference laboratories require the highest throughput and strongest automation economics.
Systems processing 240–300 samples per hour are particularly relevant to this segment.
The key purchasing parameters are increasingly:
walkaway time;
auto-release;
LIS integration;
consumable capacity;
and percentage of samples requiring manual review.
Research Laboratories and Academic Institutes
Research and academic laboratories use urinalysis platforms for biomarker investigation, method development and clinical studies.
Their commercial volume is smaller than hospital or reference laboratory demand, but they can influence adoption of emerging urine biomarkers and analytical methods.
Homecare and Near-Patient Settings
The home and near-patient segment is supported by inexpensive urine strips and connected point-of-care analyzers.
Future growth should come from digitally interpreted testing rather than purely visual strip reading.
Smartphone-assisted urine testing and connected readers can improve standardization and support remote chronic disease monitoring.
Regional Analysis
North America
North America remains the largest regional market within the DataM Intelligence framework.
The region combines high routine-testing volume with rapid adoption of integrated laboratory automation.
The U.S. burden of kidney disease provides a substantial clinical foundation: approximately 37 million adults have CKD, and around 87% do not know they have the condition.
The region also became a major innovation market in 2026 when Beckman Coulter launched the DxU 1800 fully automated urinalysis system in the United States.
Its DxU 1800c chemistry analyzer processes up to 300 samples per hour and integrates with automated microscopy.
North American growth should therefore be driven increasingly by:
replacement of fragmented chemistry and microscopy systems;
high-volume reference laboratory consolidation;
kidney-risk testing;
and automation designed to reduce manual review.
Europe
Europe represents a mature urinalysis market with significant laboratory automation penetration.
The strongest commercial trend is expansion of digital and compact systems beyond the largest centralized laboratories.
Sysmex Europe launched the UC-1100 semi-automated urine chemistry analyzer in April 2026, targeting laboratories, clinics and near-patient workflows that require compact chemistry automation and stronger data traceability.
Siemens' Atellica UAS 60 also supports this mid-volume transition with up to 60 samples per hour from a compact digital microscopy platform.
European demand should increasingly divide between large fully automated laboratories and smaller facilities upgrading from manual sediment microscopy.
Asia-Pacific
Asia-Pacific is the fastest-growing regional market within the existing DataM framework.
The region benefits from expanding diagnostic laboratory infrastructure, high diabetes and kidney disease burden, increasing hospital automation and strong local diagnostic manufacturing capability.
Japan is particularly important because Sysmex and ARKRAY maintain substantial urinalysis technology portfolios.
Sysmex's current UN-Series integrates chemistry, fluorescent flow cytometry and digital imaging within scalable configurations.
ARKRAY maintains a broad portfolio spanning urine test strips and multiple urinalysis analyzers, supporting both laboratory and lower-throughput settings.
India and China should provide additional opportunity as diagnostic chains move from manual microscopy toward standardized automated platforms.
Middle East and Africa
The Middle East and Africa represent a more fragmented market.
Large private hospital networks and tertiary healthcare facilities can support fully automated chemistry and sediment platforms.
Smaller laboratories remain more dependent on semi-automated strip readers and manual microscopy.
The strongest opportunity lies in scalable platforms that allow laboratories to begin with chemistry automation and add digital sediment analysis as volume increases.
Competitive Landscape
Key companies include Siemens Healthineers, Beckman Coulter, Sysmex Corporation, Roche Diagnostics, ARKRAY, Erba Mannheim, URIT Medical Electronic, DIRUI, Cardinal Health, EKF Diagnostics and other regional urinalysis technology suppliers.
Competition is increasingly divided across four strategic models.
Integrated automation suppliers compete around chemistry + sediment workflows.
High-throughput chemistry suppliers compete around sample volume and consumable economics.
Digital sediment specialists compete around reduction of manual microscopy.
Point-of-care suppliers compete around simplicity, connectivity and decentralized testing.
Future leadership will increasingly depend on how much of the total urinalysis workflow a company can control.
Beckman Coulter
Beckman Coulter made one of the most important urinalysis moves of 2026 with the U.S. launch of the DxU 1800 System.
The platform combines the new DxU 1800c urine chemistry analyzer with the company's established microscopy architecture.
The chemistry analyzer processes up to 300 samples per hour, stores up to 2 million sample results and 100,000 strip images, and provides onscreen strip-image review.
The wider microscopy system is designed to reduce manual microscopic review, with the company reporting rates below 3% in applicable validated workflows.
The company's strategic direction is therefore clear:
more chemistry throughput + fewer manual reviews + integrated microscopy + kidney-related chemistry expansion.
Siemens Healthineers
Siemens maintains one of the broadest urinalysis portfolios, covering point-of-care strips, chemistry analyzers and digital sediment systems.
CLINITEK Novus processes up to 240 samples per hour and can load 200 tubes simultaneously.
The Atellica 1500 combines this urine chemistry architecture with automated digital sediment imaging and includes albumin and creatinine-related kidney parameters in compatible configurations.
The compact Atellica UAS 60 extends digital urine sediment testing into lower-volume laboratories, supporting up to 60 samples per hour from a footprint of roughly 0.1 m².
Siemens is therefore positioned across the full throughput spectrum.
Sysmex Corporation
Sysmex competes through a modular urinalysis architecture built around fluorescent flow cytometry, chemistry and digital imaging.
Its UN-Series supports fully automated start-to-finish workflows with minimal hands-on time.
The UF-5000 uses fluorescent flow cytometry for automated urine particle differentiation.
UD-10 provides digital particle images.
UN-2000 combines particle counting and chemistry.
UN-9000 adds rules-based reflex capability.
In April 2026, Sysmex Europe launched the UC-1100 semi-automated urine chemistry analyzer to strengthen compact and near-patient workflow coverage.
This gives Sysmex one of the market's clearest modular escalation strategies, allowing laboratories to build automation according to sample volume.
Roche Diagnostics
Roche maintains a strong urine chemistry and sediment-analysis portfolio through its cobas urinalysis systems.
The cobas u 601 provides fully automated strip analysis at up to 240 samples per hour with twelve onboard parameters.
The cobas u 701 automated sediment analyzer processes up to 116 samples per hour.
Roche also supports lower-throughput settings through semi-automated cobas u 411 and Urisys platforms.
The company's competitive position is therefore built around scalable urinalysis from compact chemistry testing through fully automated central-laboratory analysis.
Recent Developments Reshaping the Market
In April 2026, Sysmex Europe launched the UC-1100 semi-automated urine chemistry analyzer, extending automation into routine laboratories, clinics and near-patient testing environments.
In July 2026, Beckman Coulter launched the DxU 1800 System in the United States, combining a new urine chemistry analyzer with automated microscopy. The DxU 1800c processes up to 300 samples per hour.
At ADLM 2026, Sysmex highlighted the UN-Series as a fully automated urinalysis workflow integrating dipstick testing, sediment analysis and confirmatory digital imaging.
CDC's 2026 kidney-disease update estimates that 37 million U.S. adults have CKD and 87% remain unaware of their condition, reinforcing the importance of routine urine testing capable of identifying early kidney damage.
